Top
Summary
All studies
Mortality
Ventilation
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchDimethyl fumarateDimethyl fumarate (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

Outcomes in COVID-19 dimethyl fumarate studies

0 0.5 1 1.5+ All studies -3% 1 713 Improvement, Studies, Patients Relative Risk Mortality -3% 1 713 Ventilation -20% 1 575 RCTs -3% 1 713 Late -3% 1 713 Dimethyl fumarate for COVID-19 c19early.org September 2025 Favorsdimethyl fumarate Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY Horby (RCT) -3% 1.03 [0.71-1.48] death 61/356 57/357 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Late treatment -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk All studies -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk 1 dimethyl fumarate COVID-19 study c19early.org September 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Effect extraction pre-specified(most serious outcome) Favors dimethyl fumarate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY Horby (RCT) -3% 1.03 [0.71-1.48] 61/356 57/357 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Late treatment -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk All studies -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk 1 dimethyl fumarate COVID-19 mortality result c19early.org September 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Favors dimethyl fumarate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY Horby (RCT) -20% 1.20 [0.56-2.54] 14/284 12/291 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.65 Late treatment -20% 1.20 [0.56-2.54] 14/284 12/291 20% higher risk All studies -20% 1.20 [0.56-2.54] 14/284 12/291 20% higher risk 1 dimethyl fumarate COVID-19 mechanical ventilation result c19early.org September 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.65 Favors dimethyl fumarate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY Horby (RCT) -3% 1.03 [0.71-1.48] death 61/356 57/357 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Late treatment -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk All studies -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk 1 dimethyl fumarate COVID-19 serious outcome c19early.org September 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Effect extraction pre-specified(most serious outcome) Favors dimethyl fumarate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY Horby (RCT) -3% 1.03 [0.71-1.48] death 61/356 57/357 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Late treatment -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk All studies -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk 1 dimethyl fumarate COVID-19 Randomized Controlled Trial c19early.org September 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Effect extraction pre-specified(most serious outcome) Favors dimethyl fumarate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY Horby (RCT) -3% 1.03 [0.71-1.48] 61/356 57/357 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Late treatment -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk All studies -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk 1 dimethyl fumarate COVID-19 RCT mortality result c19early.org September 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Favors dimethyl fumarate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY Horby (RCT) -3% 1.03 [0.71-1.48] death 61/356 57/357 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Late treatment -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk All studies -3% 1.03 [0.71-1.48] 61/356 57/357 3% higher risk 1 dimethyl fumarate COVID-19 peer reviewed studies c19early.org September 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.87 Effect extraction pre-specified(most serious outcome) Favors dimethyl fumarate Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ RECOVERY Horby (RCT) -3% 1.03 [0.71-1.48] death 61/356 57/357 Improvement, RR [CI] Treatment Control RECOVERY Horby (RCT) 2% 0.98 [0.64-1.48] death 47/356 45/357 RECOVERY Horby (RCT) -20% 1.20 [0.56-2.54] ventilation 14/284 12/291 RECOVERY Horby (RCT) -12% 1.12 [0.86-1.47] 7-point status 284 (n) 291 (n) Dimethyl fumarate COVID-19 outcomes c19early.org September 2025 Favors dimethyl fumarate Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit